Baiyunshan Receives SSE Approval for Guangzhou Pharmaceutical Receivables ABS Listing

Stock News03-16

Baiyushan PH (00874) announced that on March 13, 2026, the company received a no-objection letter from the Shanghai Stock Exchange (SSE) forwarded by Industrial Securities Asset Management Co., Ltd. The letter confirms that the asset-backed securities for the Xingzheng Yuanrong-Guangzhou Pharmaceutical Receivables Phases 5-9 Special Asset-Backed Plan meet the SSE's listing requirements, and the exchange has no objection to their listing and transfer. The asset-backed securities will be issued in multiple tranches, adopting a non-renewable issuance structure, with a total issuance amount not exceeding RMB 3 billion. The first tranche must be completed within 12 months from the date of the no-objection letter. The letter remains valid for 24 months from its issuance date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187845305?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187845305","market":"sg","top_or_hot":-1,"title":"Baiyunshan Receives SSE Approval for Guangzhou Pharmaceutical Receivables ABS Listing","media":"Stock News","content":"<p>Baiyushan PH (00874) announced that on March 13, 2026, the company received a no-objection letter from the Shanghai Stock Exchange (SSE) forwarded by Industrial Securities Asset Management Co., Ltd. The letter confirms that the asset-backed securities for the Xingzheng Yuanrong-Guangzhou Pharmaceutical Receivables Phases 5-9 Special Asset-Backed Plan meet the SSE's listing requirements, and the exchange has no objection to their listing and transfer. The asset-backed securities will be issued in multiple tranches, adopting a non-renewable issuance structure, with a total issuance amount not exceeding RMB 3 billion. The first tranche must be completed within 12 months from the date of the no-objection letter. The letter remains valid for 24 months from its issuance date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan Receives SSE Approval for Guangzhou Pharmaceutical Receivables ABS Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan Receives SSE Approval for Guangzhou Pharmaceutical Receivables ABS Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-16 18:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Baiyushan PH (00874) announced that on March 13, 2026, the company received a no-objection letter from the Shanghai Stock Exchange (SSE) forwarded by Industrial Securities Asset Management Co., Ltd. The letter confirms that the asset-backed securities for the Xingzheng Yuanrong-Guangzhou Pharmaceutical Receivables Phases 5-9 Special Asset-Backed Plan meet the SSE's listing requirements, and the exchange has no objection to their listing and transfer. The asset-backed securities will be issued in multiple tranches, adopting a non-renewable issuance structure, with a total issuance amount not exceeding RMB 3 billion. The first tranche must be completed within 12 months from the date of the no-objection letter. The letter remains valid for 24 months from its issuance date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0097","symbol_name":"医药电商","start_time":0,"source_url":"","article_id":"1187845305","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187845305","pubTimestamp":1773657074,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Baiyushan PH (00874) announced that on March 13, 2026, the company received a no-objection letter from the Shanghai Stock Exchange (SSE) forwarded by Industrial Securities Asset Management Co., Ltd....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","161027":"证券","600332":"白云山","BK0097":"医药电商","BK0239":"医药制造","BK1197":"保健护理产品经销商","BK0096":"民营医院","00874":"白云山","BK1521":"挪威政府全球养老基金持仓","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0028":"国家队","BK1191":"制药","09939":"开拓药业-B","BK1161":"生物科技","BK0175":"白马股","BK1515":"抗疫概念","BK1606":"中医药概念","BK0070":"员工持股","BK1574":"生物医药B类股","BK0196":"行业龙头"},"translate_title":"白云山广州医药应收款ABS上市获上交所批文","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"161027":1,"600332":1,"09939":1,"00874":1},"content_text":"Baiyushan PH (00874) announced that on March 13, 2026, the company received a no-objection letter from the Shanghai Stock Exchange (SSE) forwarded by Industrial Securities Asset Management Co., Ltd. The letter confirms that the asset-backed securities for the Xingzheng Yuanrong-Guangzhou Pharmaceutical Receivables Phases 5-9 Special Asset-Backed Plan meet the SSE's listing requirements, and the exchange has no objection to their listing and transfer. The asset-backed securities will be issued in multiple tranches, adopting a non-renewable issuance structure, with a total issuance amount not exceeding RMB 3 billion. The first tranche must be completed within 12 months from the date of the no-objection letter. The letter remains valid for 24 months from its issuance date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187845305","isCrawlerRequest":true}